Please ensure Javascript is enabled for purposes of website accessibility

Monsanto Picks Seminis

By Brian Gorman – Updated Nov 16, 2016 at 2:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Monsanto's latest acquisition provides a sensible avenue for growth.

Monsanto (NYSE:MON) is branching out via a new acquisition. Investors apparently are less than thrilled about the deal, because they sent the stock down almost 7% in trading yesterday, but they may want to give this purchase some time to germinate.

The agricultural biotechnology outfit disclosed early Monday that it will buy privately held Seminis Inc., the world's largest fruit and vegetable seed developer, in a $1.4 billion transaction. Monsanto will pay $1 billion in cash for Seminis as well as assume $400 million in debt.

Evidently, the price that Monsanto is paying for Seminis is what is raising objections. As for Seminis' financial performance, the firm posted sales of $526 million in fiscal 2004 and booked a net loss of $16.3 million. Still, the Oxnard, California, company's potential for growth looks promising. Revenue grew 10.1% in fiscal 2004 from 2003, while losses were nearly cut in half. Furthermore, its fiscal 2004 loss reflects $45 million in non-cash charges.

For Monsanto, the deal is not expected to affect fiscal 2005 earnings, probably because the company does not expect the purchase to close until its fiscal third quarter, which ends in May. Free cash flow for 2005, however, is now projected to be negative $750 million versus a previous projection of positive $600 million. Nevertheless, the near-term dent in free cash flow may be well worth the benefit in the long run.

Monsanto's concentration on selling genetically altered seeds has already yielded impressive results. According to Reuters, the firm controls up to one-third of the U.S. corn seed market, if its licensing agreements covering germplasm and technology traits are taken into account. Meanwhile, the company is making progress in China and protecting its turf in South America.

Its competitors, including Bayer (NYSE:BAY) and Syngenta (NYSE:SYT) are formidable, though, and Monsanto needs to continue to diversify to stay competitive. The Seminis deal will allow it to do just that. For now, Monsanto plans to use conventional breeding to develop Seminis' seeds, but has left the door open to using its biotechnology expertise to create improved fruit and vegetable lines. Over the long term, the harvest for Monsanto could be bountiful.

For related Fool analysis, see:

Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Monsanto Company Stock Quote
Monsanto Company
MON

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.